Search

Displaying results 1161 - 1170 of 10000 in total
  1. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution … Dihydroergotamine is used as an abortive therapy for migraines.

    Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
  2. Drug

    Irinotecan

    go.drugbank.com/drugs/DB00762
    ApprovedInvestigational

    [A263381] As an anticancer drug, irinotecan was first commercially available in Japan in 1994 to treat various cancers such as lung, cervical and ovarian cancer. … [L50181, L50186, L50201] Irinotecan liposome was approved by the FDA in February 2024.[L50186] The active metabolite SN-38 is also a potent inhibitor of DNA topoisomerase I.

  3. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.

    Synonyms: isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl)(3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinateCategories: Receptors, Prostaglandin E, EP2 Subtype, agonists
  4. Drug

    Acetylcarnitine

    go.drugbank.com/drugs/DB08842
    ApprovedInvestigational

    Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans. … Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India

  5. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections. … [A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].

  6. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    metastatic breast cancer with one or more alterations in PIK3CA/AKT1/PTEN gene(s) in combination with [fulvestrant]. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

  7. Drug

    Dexamethasone

    go.drugbank.com/drugs/DB01234
    ApprovedInvestigationalVet approved

    [L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms … Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]

    Mixtures: TOBRAMICINA E DESAMETASONE EG, TOBRAMICINA E DESAMETASONE DOC GENERICIProducts: SOLUTIO CORDES DEXA N, DEXA RHINOSPRAY N SINE
  8. Drug

    Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14389
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer Fertigspritze
  9. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023.

  10. Drug

    Streptococcus pneumoniae type 19a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10337
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche